{"disease":{"id":"breast-atypical-hyperplasia","name":"breast atypical hyperplasia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05178498","title":"Impact of Dietary Inflammatory Potential on Breast Cancer Risk","phase":"","overall_status":"RECRUITING","enrollment_count":960,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT01357772","title":"Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Andrea DeCensi","has_results":false},{"nct_id":"NCT06184750","title":"Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07499999","title":"Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":140,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT01052740","title":"X-Ray Mammography Standard of Care Protocol","phase":"","overall_status":"COMPLETED","enrollment_count":108,"lead_sponsor_name":"National Institutes of Health Clinical Center (CC)","has_results":false},{"nct_id":"NCT05941520","title":"Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06195306","title":"Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":66,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04570956","title":"Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":65,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05755269","title":"Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03323658","title":"Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}